Related Experiment Video

Updated: Jul 11, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines

Shipra Rastogi1, Sarmistha Banerjee, Srikumar Chellappan

  • 1Drug Discovery Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Cancer Letters
|October 4, 2007
PubMed

Insights

Antibodies targeting glucose transporters (Gluts), particularly Glut-1, effectively inhibited cancer cell proliferation and boosted chemotherapy efficacy in breast and lung cancer models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glucose transporters (Gluts) are crucial for cellular glucose uptake.
  • Tumor cells, including non-small cell lung cancer (NSCLC) and breast cancer, often exhibit overexpression of Glut-1.
  • Targeting Glut-1 presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To investigate the anti-proliferative and pro-apoptotic effects of anti-Glut-1 antibodies.
  • To evaluate the potential of anti-Glut-1 antibodies to enhance the efficacy of conventional chemotherapies.

Main Methods:

  • Incubation of NSCLC and breast cancer cell lines with anti-Glut-1 antibodies.
  • Co-incubation with chemotherapy drugs: cisplatin, paclitaxel, and gefitinib.
  • Assessment of cell proliferation inhibition and apoptosis induction.

Main Results:

  • Anti-Glut-1 antibodies alone inhibited proliferation by 50% in NSCLC and 75% in breast cancer cell lines.
  • Antibodies potentiated the anti-proliferative effects of cisplatin, paclitaxel, and gefitinib.
  • Demonstrated inhibition of proliferation and induction of apoptosis by anti-Glut-1 antibodies.

Conclusions:

  • Anti-Glut-1 antibodies exhibit significant anti-tumor activity by inhibiting proliferation and inducing apoptosis.
  • These antibodies can enhance the effectiveness of existing cancer therapies.
  • Further research into anti-Glut-1 antibodies as a cancer treatment is warranted.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...